UNSPSC 51142521: Ciladopa

This classification denotes a dopamine agonist with the molecular formula C21H26N2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier D09L486R3J, chemically known as 2,4,6-cycloheptatrien-1-one, 2-(4-(2-(3,4-dimethoxyphenyl)-2-hydroxyethyl)-1-piperazinyl)-, (s)- but generally known as ciladopa, which bears US NIH Compound Identifier 133371. European Medicines Agency schedules Ciladopa in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06262MIG.

UNSPSC 51142521 Ciladopa is a Commodity code that encompasses pharmaceutical products, particularly generic medications and over-the-counter formulations procured through state and local health agencies, cooperative purchasing networks, and community health programs. State and local governments buying under this code source branded and generic pharmaceuticals, naloxone and drug deactivation systems, and specialty pharmacy products through competitive bidding and cooperative agreements. Issuing bodies include state health and human services commissions, county health departments, and multistate cooperative purchasing alliances. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) stands out as a significant repeat procurement vehicle, aggregating demand across state and local members to negotiate volume pricing with manufacturers and manage distribution through authorized wholesalers.

Recent activity spans Florida, Minnesota, Texas, and Oregon. Seminole County, Florida released an IFB on June 30, 2026 (response due July 26, 2026 — note: the source lists a conflicting due date of July 26, 2023, which appears inconsistent with the June 2026 posting date) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the county health building; vendors must include all shipping costs and comply with E-Verify and drug-free workplace requirements. The Texas Health and Human Services Commission issued an RFI on April 3, 2026 to explore direct-to-manufacturer prescription programs and vendor capabilities for establishing direct contracts with self-insured health plans outside traditional pharmacy benefit manager and group purchasing organization channels. MMCAP, administered by the Minnesota Department of Administration, posted an RFP on January 20, 2026 (response due March 26, 2026) for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local facilities in Minnesota and Oregon through three authorized wholesalers; evaluation weighs price competitiveness at 75 percent, with awards effective July 1, 2026. All three solicitations emphasize compliance with FDA and federal supply chain regulations, insurance requirements, and fixed or negotiated pricing structures.